Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Sarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Carboplatin 106Pemetrexed 74Paclitaxel 58Cisplatin 52Erlotinib Hydrochloride 51Radiotherapy 49Docetaxel 43Gemcitabine 41Bevacizumab 41pembrolizumab 30Nivolumab 25Radiosurgery 21Etoposide 20durvalumab 13Cetuximab 13Specimen Handling 12Ipilimumab 12Magnetic Resonance Spectroscopy 11Gefitinib 11Vinorelbine 10Taxes 10Radiation 10Albumin-Bound Paclitaxel 10osimertinib 9Biopsy 9vandetanib 8Topotecan 7Platinum 7Irinotecan 7Drug Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lung Neoplasms × amrubicin × Clear all
NCT02481830 2023-07-27

CheckMate331

Bristol-Myers Squibb

Phase 3 Completed
569 enrolled 13 charts
Thoracic

Lung Neoplasms

NCT00660504 2014-07-18

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Sumitomo Pharma (Suzhou) Co., Ltd.

Phase 3 Completed
300 enrolled 10 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡